Prostate Cancer

Cancer statistics, 1996

1996 • 1,807 citations

Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update

1997 • 1,621 citations

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1996 • 1,584 citations

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1997 • 1,555 citations

Intake of Carotenoids and Retino in Relation to Risk of Prostate Cancer

1995 • 1,356 citations

Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer

1995 • 1,251 citations

Longitudinal Evaluation of Prostate-Specific Antigen Levels in Men With and Without Prostate Disease

1992 • 1,065 citations

Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search

1996 • 834 citations

Evaluation of Percentage of Free Serum Prostate-Specific Antigen to Improve Specificity of Prostate Cancer Screening

1995 • 682 citations

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial

1997 • 666 citations

Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer

1993 • 526 citations

Risk Factors for Urinary Incontinence after Radical Prostatectomy

1996 • 519 citations

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the radiation therapy oncology group

1995 • 498 citations

Age-Specific Reference Ranges for Serum Prostate-Specific Antigen in Black Men

1996 • 423 citations

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer.

1993 • 400 citations

Free, Complexed and Total Serum Prostate Specific Antigen: The Establishment of Appropriate Reference Ranges for their Concentrations and Ratios

1995 • 333 citations

Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer

1995 • 310 citations

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.

1997 • 274 citations

Epidemiology of prostate cancer

1997 • 254 citations

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate.

1994 • 225 citations

Strontium-89 chloride for pain palliation in prostatic skeletal malignancy

1991 • 219 citations

Ketoconazole Retains Activity in Advanced Prostate Cancer Patients with Progression Despite Flutamide Withdrawal

1997 • 200 citations

Long-term Survival and Mortality in Prostate Cancer Treated with Noncurative Intent

1995 • 197 citations

Detection of circulating tumor cells in men with localized prostate cancer.

1994 • 180 citations

Prostate-specific antigen decline after casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome

1994 • 174 citations

The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer

1995 • 174 citations

Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer

1995 • 151 citations

Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study

1996 • 147 citations

Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2–3 N0 M0 prostatic carcinoma

1997 • 138 citations

Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone.

1989 • 133 citations

The Prostate Cancer Intervention Versus Observation Trial (PIVOT).

1997 • 131 citations

Deferred Treatment in Clinically Localised Prostatic Carcinoma

1992 • 118 citations

The National Cancer Data Base report on longitudinal observations on prostate cancer

1996 • 108 citations

Preoperative Reverse Transcriptase Polymerase Chain Reaction for Prostate Specific Antigen Predicts Treatment Failure Following Radical Prostatectomy

1996 • 103 citations

Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control.

1996 • 103 citations

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer.

1995 • 102 citations

Neoadjuvant hormonal therapy: The Canadian experience

1997 • 95 citations

Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer

1995 • 90 citations

Standard Versus Age-Specific Prostate Specific Antigen Reference Ranges Among Men With Clinically Localized Prostate Cancer: A Pathological Analysis

1996 • 85 citations

Prostate Specific Antigen after Gonadal Androgen Withdrawal and Deferred Flutamide Treatment

1995 • 84 citations

Erectile functioning of men treated for prostate carcinoma

1997 • 81 citations

Radiotherapy for High Grade Clinically Localized Adenocarcinoma of the Prostate

1996 • 77 citations

Intermittent Androgen Deprivation for Clinically Localized Prostate Cancer: Initial Experience

1998 • 72 citations

Free, complexed and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate

1996 • 60 citations

WHY NEOADJUVANT ANDROGEN DEPRIVATION PRIOR TO RADICAL PROSTATECTOMY IS UNNECESSARY

1996 • 59 citations

Development and validation of a pharmacokinetically based fixed dosing scheme for suramin.

1995 • 56 citations

Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma

1997 • 54 citations

Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone-resistant prostate cancer.

1996 • 50 citations

Lack of Correlation Between Prostate-Specific Antigen and the Presence of Measurable Soft Tissue Metastases in Hormone-Refractory Prostate Cancer

1996 • 50 citations

Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area: 1973-1994

1996 • 48 citations

Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.

1995 • 47 citations

Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy.

1996 • 40 citations

Clinical usefulness of free PSA fraction as an indicator of prostate cancer

1995 • 37 citations

Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group.

1995 • 37 citations

Pitfalls in interpreting prostate specific antigen velocity.

1996 • 36 citations

Surgery with adjuvant irradiation in patients with pathologic stage C adenocarcinoma of the prostate

1995 • 23 citations

A new look at radionuclides therapy in metastatic disease of bone (review and prospects).

1988 • 13 citations